Funding
Series B · Biotech

Crossbow Therapeutics raises $77M Series B

Crossbow Therapeutics raised $77 million in Series B financing announced in March.

Updated Oct 16, 2026By RoundOS Funding desk

Taiho Ventures, Arkin Bio Capital, Sixty Degree Capital, Hamilton Square Partners, LifeLink Ventures, Libbs Ventures, Blood Cancer United’s Therapy Acceleration Program, MPM BioImpact, Pfizer Ventures, BVF Partners, Polaris Partners, Eli Lilly and Mirae Asset Venture Investment are among its backers.

The company develops antibody therapies for cancer.

Funding history

Series B · This round$77M

Sources

  1. Crossbow Therapeuticsprojectstartups.com
  2. businesswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Knowledge Work

Tokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.

¥4.8BSeries C debt second close · Oct 23, 2026

Related